BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ) + BCG( 50mg/Instillation)

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Non-muscle Invasive Bladder Cancer

Conditions

Non-muscle Invasive Bladder Cancer

Trial Timeline

Jul 21, 2014 → Dec 1, 2038

NCT ID

NCT02138734

About BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ) + BCG( 50mg/Instillation)

BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ) + BCG( 50mg/Instillation) is a phase 1/2 stage product being developed by ImmunityBio for Non-muscle Invasive Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02138734. Target conditions include Non-muscle Invasive Bladder Cancer.

What happened to similar drugs?

0 of 4 similar drugs in Non-muscle Invasive Bladder Cancer were approved

Approved (0) Terminated (0) Active (4)

🔄Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3

🔄Durvalumab + BCGAstraZenecaPhase 3

🔄Pembrolizumab + BCGMerckPhase 3

🔄PF-06801591 + Bacillus Calmette-GuerinPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02138734	Phase 1/2	Recruiting	Jul 21, 2014	Dec 1, 2038	Non-muscle Invasive Bladder Cancer

Competing Products

18 competing products in Non-muscle Invasive Bladder Cancer

See all competitors

Product	Company	Stage	Hype Score
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)	AstraZeneca	Phase 3	44
Durvalumab + BCG	AstraZeneca	Phase 3	44
Durvalumab + Monalizumab	AstraZeneca	Phase 2	42
Pembrolizumab + BCG	Merck	Phase 3	44
Pembrolizumab	Merck	Phase 1/2	24
Sacituzumab tirumotecan + Rescue medication + Supportive care measures	Merck	Phase 1/2	39
Eciskafusp Alfa + BCG Medac Strain	Roche	Phase 1	21
PF-06801591 + Bacillus Calmette-Guerin	Pfizer	Phase 3	44
PF-08052667 + Sasanlimab + BCG + PF-02921367	Pfizer	Phase 1	36
N-803 and BCG + N-803 and Gemcitabine	ImmunityBio	Phase 2	39
Cretostimogene Grenadenorepvec	CG Oncology	Phase 2	39
Cretostimogene Grenadenorepvec	CG Oncology	Pre-clinical	27
UGN-301 + UGN-201 + Gemcitabine	UroGen Pharma	Phase 1	23
AU-011	Aura Biosciences	Phase 1	26
TARA-002	Protara Therapeutics	Phase 1	19
TARA-002	Protara Therapeutics	Phase 2	32
TARA-002	Protara Therapeutics	Phase 1	19
PD-L1/IDO Peptide Vaccine + Pembrolizumab	IO Biotech	Phase 1	26